Table.1.
Characteristics of the included studies, in which patients were transitioned from tumor necrosis factor-α inhibitor originator to the corresponding biosimilar
| Characteristic | Publications (n = 37) |
|---|---|
| Publication characteristics | |
| Funding | |
| Industry | 8 (21.6) |
| Public | 29 (78.4) |
| Study design characteristics | |
| Type of study | |
| Cohort | 36 (97.3) |
| Case series | 1 (2.7) |
| Case–control | NA |
| Other | NA |
| Geographical location of study | |
| Europe | 34 (91.9) |
| North America (USA) | 2 (5.4) |
| Asia | 1 (2.7) |
| Year of start transitioning | |
| 2012 | 1 (2.7) |
| 2013 | – |
| 2014 | 3 (8.1) |
| 2015 | 7 (18.9) |
| 2016 | 13 (35.1) |
| 2017 | 5 (13.5) |
| 2018 | 4 (10.8) |
| NR | 4 (10.8) |
| Duration of follow-up, months | 12.0 (6.00–15.1) |
| Randomization of patients (yes) | 1 (2.7) |
| Treatment blinded for patients (yes) | – |
| Number of patients included | 94 (45–192) |
| Study population characteristics | |
| Age, years | |
| < 45 | 12 (32.4) |
| 45–55 | 15 (40.5) |
| > 55 | 9 (24.3) |
| Not reported | 1 (2.7) |
| % Females | 53.6 ± 13.0 |
| Indication | |
| Rheumatic disease | 22 (59.5) |
| Inflammatory bowel disease | 7 (18.9) |
| Multiple indications | 4 (10.8) |
| Other | 4 (10.8) |
| Type of TNFα inhibitor | |
| Etanercept | 11 (29.7) |
| Infliximab | 23 (62.2) |
| Adalimumab | 2 (5.4) |
| Multiple | 1 (2.7) |
| Years since first diagnosis | |
| < 10 | 7 (18.9) |
| 10–15 | 10 (27.0) |
| > 15 | 6 (16.2) |
| Not reported | 14 (37.8) |
| Duration of originator treatment prior to transitioning to a biosimilar, years | |
| < 5 | 14 (37.8) |
| 5–10 | 14 (37.8) |
| > 10 | 1 (2.7) |
| Not reported | 8 (21.6) |
Data are presented as n (%), mean ± standard deviation, or median (interquartile range) unless otherwise indicated
NA not applicable, NR not reported, TNF tumor necrosis factor